Decitabine

For research use only. Not for use in humans.

製品コードS1200 別名:Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine

Decitabine化学構造

CAS No. 2353-33-5

Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 27700 あり
JPY 16900 あり
JPY 30200 あり
JPY 55100 あり
JPY 96600 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(89)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MonNSpVv[3Srb36gRZN{[Xl? M1S3TlAvPcLizszN MlixNlQhcA>? Mojoe4F1\XJ? NUOy[XV1dW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? NXLZU2g4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPENE42NzJwNT:1JO69VQ>? MWiyOE81QC95MjDo M1XZSZdifGW{ NVXRc|E3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109 NYHBV2l4TnWwY4Tpc44hSXO|YYm= NXi4XW5iOC53wrFOwG0> NUja[20zPi9zMj:yOEBp Mmrme4F1\XJ? NV72SG9wcW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NVLPdWI2TnWwY4Tpc44hSXO|YYm= MVKwMlXDqM7:TR?= M2\SelI1KGh? MWj3ZZRmeg>? MXXpcohq[mm2czDj[YxtKGmwdnHzbY9v NIqxZ3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
Eca109 NGrQb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHwXFIxNjYEoN88US=> M2rFfFI1KGh? NGDjNmF4[XSnch?= NI\YR4NqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109 NXHX[5F6TnWwY4Tpc44hSXO|YYm= MYSwMlUwOSEQvF2= NGrMUJQzPCCq MUT3ZZRmeg>? MYDk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
SW1116  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\sNnFKOC53L{GvNk82KM7:TR?= NEXYNlQ1QCCq Ml3KSG1UVw>? Mm[5[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NWi1VlJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
LOVO NF7NS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlUwOS9{L{Wg{txO Mm\POFghcA>? MojHSG1UVw>? MV3lcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NEj1fWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
SW1116  NIiyXIVHfW6ldHnvckBCe3OjeR?= NXnIRWtPOTBizszN M1S5VVQ5KGh? MYfEUXNQ NFfTdpRqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? M3jpWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO Mn3kSpVv[3Srb36gRZN{[Xl? NYDme3NPOTBizszN NHLNUpI1QCCq NWnyTVB3TE2VTx?= MXfpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
SW1116  NFTkNXJCeG:ydH;zbZMhSXO|YYm= NFfNWWUyOCEQvF2= Mnr3OFghcA>? MnH5SG1UVw>? MV7lcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO MlL4RZBweHSxc3nzJGF{e2G7 NXjEN2t2OTBizszN M1roc|Q5KGh? MlLSSG1UVw>? MkXM[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226 NFHpTodCeG:ydH;zbZMhSXO|YYm= MUmxM|Ih|ryP NIXMXnA1QC95Mj:5OkBp MkS3SG1UVw>? NYP2NmtucW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NELRRlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
OPM-2  MoLyRZBweHSxc3nzJGF{e2G7 MXWxM|Ih|ryP MWK3Nk86Pi9zMkCgbC=> MVLEUXNQ NULsUlN5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3  MXXBdI9xfG:|aYOgRZN{[Xl? NV\oOFBwOC53L{Gg{txO NXT1e2lCOjRxNEigbC=> NYLCO2hZTE2VTx?= MoHSbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NG\5eIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
NCI-H929  Mm\ZRZBweHSxc3nzJGF{e2G7 MYqxM|Ih|ryP Ml3xO|IwQTZxMUKwJIg> MYjEUXNQ NXnFWIpvcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEjORVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
RPMI-8226 M1nYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nFclEwOiEQvF2= NEniV2wzPC92OD:3NkBp NVLxNGMxTE2VTx?= MXvh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NVznTmgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
OPM-2  NFW5N3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TIUlEwOiEQvF2= MUWyOE81QC95MjDo MnvjSG1UVw>? MnfmZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M4DOVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
JJN3  NH3QVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTQc3JnOC53L{Gg{txO MUeyOE81QC95MjDo NYXXdYNvTE2VTx?= M1TaboFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
NCI-H929  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HSV|EwOiEQvF2= NXjuOoMzOjRxNEivO|IhcA>? MkPWSG1UVw>? MWDh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NGTkZ3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
HeLa NIG0WGFMcW6jc3WgRZN{[Xl? NI\Wd4VMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NX7HUFZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa MUPLbY5ie2ViQYPzZZk> M2e1NWtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> M3TBXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa M2jXfWtqdmG|ZTDBd5NigQ>? M3XoN2tqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> NWq4UolVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa NIXFT2NMcW6jc3WgRZN{[Xl? M3q4VmtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> M2DNXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
NB4 NYTCeHZnTnWwY4Tpc44hSXO|YYm= NVfw[mZ7Oi53L{WvO{42NzFyIN88US=> NILFfWszPCCq NXn1XI1DTE2VTx?= MWTpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NEi3NEc,OjR2OES4O|A9N2F-
CD4+ CD25− T  MVfGeY5kfGmxbjDBd5NigQ>? MUWxM|Uh|ryP MXTy[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> M1PRWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe2N|YxLz5{NES3OlM3ODxxYU6=
BV-173 M2HFcGFxd3C2b4Ppd{BCe3OjeR?= MYCwMlI2NzBwNT:wMlc2NzFizszN MYm0PE84Oi97NjDo Mo[xxsBRSlN? NI\udJNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NEPuVXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 M2jP[GFxd3C2b4Ppd{BCe3OjeR?= MUGwMlI2NzBwNT:wMlc2NzFizszN MnzTOFgwPzJxOU[gbC=> MnXwxsBRSlN? M4fFeYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M2n2e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
HL-60 M1nDW2Fxd3C2b4Ppd{BCe3OjeR?= NH;vOGkxNjJ3L{CuOU8xNjd3L{Gg{txO NF\lOHA1QC95Mj:5OkBp MoPlxsBRSlN? NWD2S5BHcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NV;CPJo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
KG-1a M2faVGFxd3C2b4Ppd{BCe3OjeR?= M{H3elAvOjVxMD61M|AvPzVxMTFOwG0> MlSyOFgwPzJxOU[gbC=> M{TiW:KhWEKV MULpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NXyzO5ZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
BV-173 NFqyUmVHfW6ldHnvckBCe3OjeR?= M1\RVVI2OC93MEDuUS=> MoLzOFghcA>? NVHlelJPyqCSQmO= Mnu5bY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NFTVV4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
CEM NW\6UmZrTnWwY4Tpc44hSXO|YYm= MUeyOVAwPTBybl2= MmPkOFghcA>? NV7JN|I6yqCSQmO= NFX0foJqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60 MUjGeY5kfGmxbjDBd5NigQ>? MkjNNlUxNzVyMH7N M3mzbFQ5KGh? MknRxsBRSlN? NVTjfGRycW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MmPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
ML-1 MnHlSpVv[3Srb36gRZN{[Xl? NGTQXIczPTBxNUCwcm0> NIPxU|Q1QCCq M3S1fOKhWEKV NYDzWoxxcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M3XOeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
DLD-1 MoO0SpVv[3Srb36gRZN{[Xl? M37KPVI2OC93MEDuUS=> Mme4OFghcA>? NEm3UmLDqFCEUx?= MmO5[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HCT-116 NWPyd5NyTnWwY4Tpc44hSXO|YYm= MXKyOVAwPTBybl2= MWW0PEBp M3XLVOKhWEKV NHnkTGtldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NF7zRnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
U937-A/E-9/14/18  NIWxSFdCeG:ydH;zbZMhSXO|YYm= MnW5NE4xOS9yLkGvNU8yOCEQvF2= MorsOFghcA>? MkmzbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXrL[HNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N|AxPDV4PD;hQi=>
HT29 NWC2VYdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX63NkBp NFO5V3lKSzVyPUG0NFDDuTF5OTFOwG0> NWXMOJEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|IxPjFpPkK0NVczODZzPD;hQi=>
SW48 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3NkBp M{H0T2lEPTB;MUWuNuKyPi5{IN88US=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HCT116 NV\GV3FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm3NkBp M4TYWmlEPTB;MT63xtExNjRizszN NUjhRZNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|IxPjFpPkK0NVczODZzPD;hQi=>
HepG2 MoDKSpVv[3Srb36gRZN{[Xl? NUf4cXNIOC53L{Gg{txO MWqyOEBp NF\0[2hFVVOR NGLiSHN2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
LS174T M{DNemZ2dmO2aX;uJGF{e2G7 NVjJ[IUzOC53L{Gg{txO M1HifVI1KGh? MlLjSG1UVw>? MkHMcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= NVj1O3RVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
HepG2 M1rrZWFxd3C2b4Ppd{BCe3OjeR?= NWPENph3OS9zMD:xNFAh|ryP NVrGfYk3PyCm M1yzN2ROW09? NFmxU4ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1jJbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
LS174T NEjEeFRCeG:ydH;zbZMhSXO|YYm= NWjT[JdwOS9zMD:xNFAh|ryP NXPGRmwzPyCm MXTEUXNQ MmW1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3jOOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
QBC-939 MX3BdI9xfG:|aYOgRZN{[Xl? NWDafnc6OS9zMD:xNFAh|ryP M3ezbFch\A>? NW\CRoR{TE2VTx?= MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYrEUWZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
U251 NFHIPVZCeG:ydH;zbZMhSXO|YYm= NVTIc2tSOS9zMD:xNFAh|ryP NYrPR2xbPyCm NUHKTGRlTE2VTx?= MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
HL-60 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnSPZRsOSEQvF2= Mne3OFghcA>? M3XrZ4lv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w NFjke5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwNFMzPCd-MkSwNFA{OjR:L3G+
MDA‑MB‑453 M3jNcGZ2dmO2aX;uJGF{e2G7 M3TtXFAvOi9zIN88US=> NHL6bYE4OiCq NXy3cWNn[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh M{SzZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
HCC1569 MYXGeY5kfGmxbjDBd5NigQ>? MlvVNE4zNzFizszN NEjvTmE4OiCq NILkVJFk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MorUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ|OES0NlI5RC:jPh?=
BT‑474 NY\HenF4TnWwY4Tpc44hSXO|YYm= NXz4TXU5OC5{L{Gg{txO Mnj6O|IhcA>? NGruPIxk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M4jiN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
AGS NV3ZSYRuSXCxcITvd4l{KEG|c3H5 NX3rRoI4PS9zMD:yNE82OCEQvF2= NHL5PG41QMLiaNMg NEXMPW9FVVOR MkXFbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MmTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
A549 MkXJRZBweHSxc3nzJGF{e2G7 NWH2T4UyPS9zMD:yNE82OCEQvF2= MoS2OFjDqGkEoB?= NGDN[25FVVOR M1r1dIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh MnjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
AGS  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrmfG02NzFyL{KwM|UxKM7:TR?= NWXRbYpOPDkEoHlCpC=> NVnxUpY3TE2VTx?= MkjkbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg M1rYZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
Kasumi-1 M1\wZ2Fxd3C2b4Ppd{BCe3OjeR?= Mn6wNE42KM7:TR?= NWGxfI9MPDkEoHlCpC=> NX20[VFL\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NWDTeXlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
OCI-AML3 MUXBdI9xfG:|aYOgRZN{[Xl? NXOzeIFjOi53IN88US=> M4nWblQ5yqCqwrC= NVfCcHlw\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
MV4-11 Mof5RZBweHSxc3nzJGF{e2G7 NEjIUlAzNjVizszN MV60POKhcMLi NEn1c3Nl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NWXnXVdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
NK  MWDDfZRwfG:6aYT5JGF{e2G7 NV3lWIhTOC5yMj2yNEDPxE1? M1fWelUh\A>? MV\k[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm M2O0ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{K4NFg5Lz5{M{OyPFA5QDxxYU6=
NK  M3X6TGFxd3C2b4Ppd{BCe3OjeR?= M{[0ZlAvODJvMkCg{txO M3LjbVUh\A>? MWrk[YNz\WG|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ> M{jzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{K4NFg5Lz5{M{OyPFA5QDxxYU6=
NK  NY\QTZBjTnWwY4Tpc44hSXO|YYm= M{XyUVAvODFvMkCg{txO M3rUVFUh\A>? MWrjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NULDZndHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlgxQDhpPkKzN|I5ODh6PD;hQi=>
MOLT4/DNR Ml7JSpVv[3Srb36gRZN{[Xl? NGK3OIs2KM7:TR?= MorsOEBl MoTUdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NFGy[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
Jurkat/DOX M{ftfGZ2dmO2aX;uJGF{e2G7 NHLQbo82KM7:TR?= MofxOEBl NEjB[2Nz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? M4Ow[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
MOLT4/DNR Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkOzOUDPxE1? NF\yVoc1KGR? M4POO5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= M33NelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
Jurkat/DOX NGDVZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[1JO69VQ>? NVLpUYRKPCCm M4XjN5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NFnUWW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
ccRCC  NEWzXGZCeG:ydH;zbZMhSXO|YYm= Mly1NE4xOS1zMN88US=> MkLtO|IhcA>? NUn6Z45XTE2VTx?= NGfoUJJp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NFLKRoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC  MUPBdI9xfG:|aYOgRZN{[Xl? Ml\ZNE4xOS1zMN88US=> MXe3NkBp MYHEUXNQ M2jkSohieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498 NGHvS|VCeG:ydH;zbZMhSXO|YYm= NGPSPHgxNjBzLUGw{txO NIjyNZE4OiCq Ml3kSG1UVw>? MoHabY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NXTpTGpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
KIJ265T MUPBdI9xfG:|aYOgRZN{[Xl? NXPzUJNyOC5yMT2xNO69VQ>? NYD2VFRYPzJiaB?= MXfEUXNQ Ml3zbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NIq3b2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
MDA-231 MVHBdI9xfG:|aYOgRZN{[Xl? NW\YdIJ5OC5yMT2xNO69VQ>? NWHOS4lCPzJiaB?= NHf2VlRFVVOR MmK4bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NFyxVXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
BT-20 Mmf2RZBweHSxc3nzJGF{e2G7 NVTzVGY2OC5yMT2xNO69VQ>? M3zvT|czKGh? NUHSS2s3TE2VTx?= M4PpeYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
U937 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG2fldIPS1{MDFOwG0> M3fSWVI1NzR6L{eyJIg> NFnHNGNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MkPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkewNlEoRjJ{N{[3NFIyRC:jPh?=
HL60 NED3clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXizO4h6PS1{MDFOwG0> NWD5bnBNOjRxNEivO|IhcA>? M4XBeYlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M1W5e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O|AzOTxxYU6=
U937 NHjEblFCeG:ydH;zbZMhSXO|YYm= NYPuO5FmOTVizszN NHLkTlQzPC92OD:3NkBp M1TsXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkewNlEoRjJ{N{[3NFIyRC:jPh?=
HL60 MkTzRZBweHSxc3nzJGF{e2G7 M1S3VVE2KM7:TR?= MV:yOE81QC95MjDo M2nvNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
LS411N  Mnn4RZBweHSxc3nzJGF{e2G7 M3XvZ|AvPSEQvF2= M4K4N|czKGh? MVXpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR4MU[5OUc,OjJ2NkG2PVU9N2F-
MDA-MB-231 M2T3S2Fxd3C2b4Ppd{BCe3OjeR?= NVrHWJZSOTBizszN NFvEV2s1QCCq M2Du[pJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXfFO5VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
MCF-7  NUPnSlZ6SXCxcITvd4l{KEG|c3H5 M3jB[FExKM7:TR?= Mn\ZOFghcA>? NV;SeFBnemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6N{[5O{c,OjF6OEe2PVc9N2F-
A375 MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMlUh|ryP M{LmTVEwPS96IHS= NHTTXlJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NUTqeVZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
SKMEL1 M{PQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMlUh|ryP MlvHNU82NzhiZB?= MojnbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL3 NGPldlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3uNE42KM7:TR?= NXG5NIY1OS93L{ig[C=> MXPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NX3Gb21ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
SKMEL28 NHn4OJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\VOFAvPSEQvF2= M3OzfFEwPS96IHS= NI\kUpVqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= Mnz1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
MeWo NVvFU|VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[wMlUh|ryP NH[0XVEyNzVxODDk M3;s[IlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NUDWdIR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
B16 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[wMlUh|ryP MYGxM|UwQCCm MlXHbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NVjnVGNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
Ly 1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXOVmczPCCq NUTEdFBjUUN3ME23MlMh|ryP MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;JcVczPCCq MV\JR|UxRTFyLkeg{txO NYrlNWJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL6 NGf5PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPkd2ZuOjRiaB?= MXrJR|Ux97zgMkCg{txO MorBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnUS5gzPCCq MVrJR|Ux97zgMkCg{txO NX:yO2ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA NIfo[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r1OVI1KGh? M3:wb2lEPTExvK6yNEDPxE1? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 NE\UOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M335dFI1KGh? M2ftdWlEPTExvK6yNEDPxE1? MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUO0PEBp MXvJR|UxRTBwM{Sg{txO MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7 NF\LcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[2S4ZtPDhiaB?= MmLFTWM2OD1yLkCyOUDPxE1? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 NWH0TVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULhT3RJPDhiaB?= NV;tOm84UUN3MP-8olIxKM7:TR?= NYT1TXVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 NELF[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKxOFghcA>? MmrETWM2OD1zLkig{txO NUPKdWVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTjOFghcA>? M2\KcWlEPTExvK6yNEDPxE1? NXW4XIVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL2 NFfWNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rKTlQ5KGh? NVv0fm1pUUN3ME2xO{41KM7:TR?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1 NX;pXndFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX5fYpRPzJiaB?= NWK3RlMzUUN3ME2wMlAyKM7:TR?= NH\NOHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 7 NXvYdJM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO4cmk4OiCq MnLrTWM2OD1yLkCxPEDPxE1? M3G5OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL6 NHnpfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:4W3E4OiCq M2izU2lEPTB;MT62JO69VQ>? NELiN|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTZO5c3PzJiaB?= NXv2ZVdmUUN3ME2xMlIh|ryP MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
RIVA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVW3NkBp NG[0XYVKSzVy78{eNlAh|ryP NH;WOlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL2 NIK0bldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HsdlczKGh? NWfKbGFFUUN3ME2xNU4zKM7:TR?= M3nzbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
U373-MAGI MXjBcpRqfmm{YXygZZN{[Xl? M3XRUFAvOjVidH:gPEB2VQ>? MljDNkB1dyB5MjDodpM> NWTHc5ZySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBWPS2pYXegcIV3\WxiYYSgNE4zPSC2bzC4JJVOKGGodHXyJFIhfG9iN{KgbJJ{KGK7IIHQR3IhdWW2aH;k NXXTO2pMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI MnPMRY51cX[rcnHsJIF{e2G7 NHnje4ExNjJ3IITvJFghfU1? M{DPOVIhfG9iN{KgbJJ{ MVzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDWV3YuTyCyc3X1[I91gXCnZDDITXYuOSCQTEStN{Bqdm[nY4Tl[EBqdiCqdX3hckBWOzd|LV3BS2kh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHfh[{Bt\X[nbDDheEAxNjJ3IITvJFghfU1iYX\0[ZIhOiC2bzC3NkBpenNiYomgdXBEWiCvZYToc4Q> NX3sO5RqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
- 合併
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
別名 Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals Inc. April 17 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID